CA2625300C - Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio - alzheimer's disease-specific molecular biomarkers (adsmb) - Google Patents

Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio - alzheimer's disease-specific molecular biomarkers (adsmb) Download PDF

Info

Publication number
CA2625300C
CA2625300C CA2625300A CA2625300A CA2625300C CA 2625300 C CA2625300 C CA 2625300C CA 2625300 A CA2625300 A CA 2625300A CA 2625300 A CA2625300 A CA 2625300A CA 2625300 C CA2625300 C CA 2625300C
Authority
CA
Canada
Prior art keywords
cells
disease
alzheimer
phosphorylated
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2625300A
Other languages
English (en)
French (fr)
Other versions
CA2625300A1 (en
Inventor
Tapan Kumar Khan
Daniel L. Alkon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
West Virginia University
Original Assignee
Blanchette Rockefeller Neuroscience Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/246,524 external-priority patent/US7595167B2/en
Priority claimed from PCT/US2005/036014 external-priority patent/WO2007043998A1/en
Application filed by Blanchette Rockefeller Neuroscience Institute filed Critical Blanchette Rockefeller Neuroscience Institute
Priority claimed from PCT/US2006/037186 external-priority patent/WO2007047029A2/en
Publication of CA2625300A1 publication Critical patent/CA2625300A1/en
Application granted granted Critical
Publication of CA2625300C publication Critical patent/CA2625300C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2625300A 2005-10-11 2006-09-25 Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio - alzheimer's disease-specific molecular biomarkers (adsmb) Active CA2625300C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11/246,524 2005-10-11
USPCT/US2005/36014 2005-10-11
US11/246,524 US7595167B2 (en) 2005-10-11 2005-10-11 Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
PCT/US2005/036014 WO2007043998A1 (en) 2005-10-11 2005-10-11 Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio
PCT/US2006/022156 WO2007044094A1 (en) 2005-10-11 2006-06-07 Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)
USPCT/US2006/022156 2006-06-07
PCT/US2006/037186 WO2007047029A2 (en) 2005-10-11 2006-09-25 Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)

Publications (2)

Publication Number Publication Date
CA2625300A1 CA2625300A1 (en) 2007-04-26
CA2625300C true CA2625300C (en) 2018-01-02

Family

ID=37067652

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2625300A Active CA2625300C (en) 2005-10-11 2006-09-25 Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio - alzheimer's disease-specific molecular biomarkers (adsmb)

Country Status (10)

Country Link
US (1) US20180024146A1 (https=)
EP (5) EP2322936A1 (https=)
JP (1) JP4908514B2 (https=)
KR (2) KR20140002073A (https=)
AT (1) ATE431558T1 (https=)
CA (1) CA2625300C (https=)
DE (1) DE602006006855D1 (https=)
ES (5) ES2323813T3 (https=)
TW (2) TW201413246A (https=)
WO (1) WO2007044094A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002254029A1 (en) 2001-02-27 2002-09-12 Daniel L. Alkon Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation
US20050065205A1 (en) 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
US7595167B2 (en) 2005-10-11 2009-09-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
US20090029873A1 (en) 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
US20080025961A1 (en) * 2006-07-28 2008-01-31 Alkon Daniel L Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory
EP3332797A3 (en) 2007-02-09 2018-08-01 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs and other related substances on head trauma-induced memory impairment and brain injury
EP2669386A1 (en) 2008-07-28 2013-12-04 Blanchette Rockefeller Neurosciences Institute Stimulus-elicited genomic profile markers of alzheimer's disease
CA2731171C (en) 2008-07-28 2016-10-18 Blanchette Rockefeller Neurosciences Institute Pkc-activating compounds for the treatment of neurodegenerative diseases
BRPI0914859A2 (pt) * 2008-08-27 2015-11-03 Lundbeck & Co As H método para diagnosticar um distúrbio afetivo, produto de programa de computador, computador, e, método para determinar uma probabilidade de que um indivíduo de teste exiba um sintoma de um distúrbio afetivo
EP2483695A2 (en) * 2009-10-02 2012-08-08 Blanchette Rockefeller Neurosciences, Institute Abnormal alterations of pkc isozymes processing in alzheimer's disease peripheral cells
EP2483684B1 (en) * 2009-10-02 2018-04-18 Blanchette Rockefeller Neurosciences, Institute Fibroblast growth patterns to diagnose alzheimer's disease
EP2707693B1 (en) * 2011-05-12 2016-10-12 Florin V. Chirila Peripheral diagnostic methods for screening alzheimer's disease using beta amyloid and intercellular communication
EP2780316B1 (en) 2011-11-13 2020-04-15 Blanchette Rockefeller Neurosciences Institute Esters of dcpla and methods of treatment using the same
KR101351978B1 (ko) * 2012-10-30 2014-01-16 주식회사 코씨드바이오팜 참치 안구 파쇄물을 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물 및 식품 조성물
US20170023552A1 (en) * 2014-01-03 2017-01-26 Blanchette Rockefeller Neurosciences Institute Convergence of aggregation rate with validated peripheral diagnostic for alzheimer's disease
EP3600027B1 (en) 2017-03-31 2026-02-18 Neurodiagnostics LLC Lymphocyte-based morphometric test for alzheimer's disease
CA3141059A1 (en) * 2019-05-23 2020-11-26 Indiana University Research And Technology Corporation Methods for objective assessment of memory, early detection of risk for alzheimer's disease, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4374316B2 (ja) * 1993-01-25 2009-12-02 武田薬品工業株式会社 β−アミロイドまたはその誘導体に対する抗体およびその用途
US6107050A (en) 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US20030108956A1 (en) * 1993-05-03 2003-06-12 Alkon Daniel L. Cell tests for Alzheimer's disease
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US20030165481A1 (en) * 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
AU2002254029A1 (en) 2001-02-27 2002-09-12 Daniel L. Alkon Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation
US6825229B2 (en) * 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
KR100574017B1 (ko) 2003-08-11 2006-04-26 삼성전자주식회사 잉크젯 프린터의 잉크 카트리지
US7199386B2 (en) 2004-07-29 2007-04-03 General Electric Company System and method for detecting defects in a light-management film

Also Published As

Publication number Publication date
ES2588376T3 (es) 2016-11-02
ES2477284T3 (es) 2014-07-16
JP4908514B2 (ja) 2012-04-04
EP2322934B1 (en) 2016-08-31
EP2031398B1 (en) 2013-02-13
EP2031398A1 (en) 2009-03-04
ES2323813T3 (es) 2009-07-24
CA2625300A1 (en) 2007-04-26
TWI448688B (zh) 2014-08-11
EP2322936A1 (en) 2011-05-18
EP2317321A1 (en) 2011-05-04
JP2009511905A (ja) 2009-03-19
TW201413246A (zh) 2014-04-01
EP2339349A1 (en) 2011-06-29
TW200801515A (en) 2008-01-01
ES2596881T3 (es) 2017-01-12
ES2412268T3 (es) 2013-07-10
US20180024146A1 (en) 2018-01-25
ATE431558T1 (de) 2009-05-15
EP2317321B1 (en) 2014-04-02
EP2339349B1 (en) 2016-08-17
DE602006006855D1 (de) 2009-06-25
WO2007044094A1 (en) 2007-04-19
EP2322934A1 (en) 2011-05-18
KR20140002073A (ko) 2014-01-07
KR101375552B1 (ko) 2014-03-24
KR20080066785A (ko) 2008-07-16

Similar Documents

Publication Publication Date Title
US9797913B2 (en) Alzheimer's disease-specific alterations of the ERK1/ERK2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (ADSMB)
US20180024146A1 (en) Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb)
US7595167B2 (en) Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
EP1934618A2 (en) Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb)
JP2008520203A (ja) アルツハイマー病の診断および治療のためのホスファターゼ２ａ（ｐｐ２ａ）の異常
US9518995B2 (en) FKBP52-Tau interaction as a novel therapeutical target for treating the neurological disorders involving Tau dysfunction
WO2007043998A1 (en) Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio
AU2009234405A1 (en) Alzheimer's Disease-specific alterations of the ERK1/ERK2 phosphorylation ratio-Alzheimer's Disease-specific molecular biomarkers (ADSMB)
US20080221042A1 (en) Alzheimer's disease-specific alterations of the ERK1/ERK2 Phosphorylation ratio-Alzheimer's disease-specific molecular biomarkers (ADSMB)
KR20070084247A (ko) 알츠하이머 질환의 진단 및 치료를 위한 포스파타제 2ａ(ｐｐ2ａ)의 비정상

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240920

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240920

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240920

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250919

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250919